G. Schingnitz

Boehringer Ingelheim (Germany)

Publishes on Circadian rhythm and melatonin, Neurobiology and Insect Physiology Research, Neural dynamics and brain function. 19 papers and 834 citations.

19Publications

834Total Citations

Circadian rhythm and melatonin Neurobiology and Insect Physiology Research Neural dynamics and brain function Neurological disorders and treatments Parkinson's Disease Mechanisms and Treatments

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey

Christian Pifl, G. Schingnitz, Oleh Hornykiewicz|Neuroscience|1991

Cited by 223

The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment

Dieter Hinzen, Oleh Hornykiewicz, W. Kobinger et al.|European Journal of Pharmacology|1986

Cited by 184

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist

Joachim Mierau, G. Schingnitz|European Journal of Pharmacology|1992

Cited by 136

The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease

Christian Pifl, G. Schingnitz, Oleh Hornykiewicz|Neuroscience Letters|1988

Cited by 73

Selective A<sub>1</sub>-Antagonists for Treatment of Cognitive Deficits

G. Schingnitz, U. Küfner-Mühl, Helmut A. Ensinger et al.|Nucleosides and Nucleotides|1991

Cited by 55

Abstract A novel compound, KFM 19, is introduced, which turned out to be a selective adenosine A1-antagonist with good bioavailability. Its pharmacological profile suggests a high therapeutic potential for dementia and related cognitive deficits.